WO2001066087A1 - New self emulsifying drug delivery system - Google Patents
New self emulsifying drug delivery system Download PDFInfo
- Publication number
- WO2001066087A1 WO2001066087A1 PCT/SE2001/000466 SE0100466W WO0166087A1 WO 2001066087 A1 WO2001066087 A1 WO 2001066087A1 SE 0100466 W SE0100466 W SE 0100466W WO 0166087 A1 WO0166087 A1 WO 0166087A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- pharmaceutical composition
- surfactant
- pharmaceutical
- composition according
- Prior art date
Links
- 0 CC(C(OCCCC*)=O)c1ccc(cc(cc2)OC)c2c1 Chemical compound CC(C(OCCCC*)=O)c1ccc(cc(cc2)OC)c2c1 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Definitions
- the present invention is directed to a new pharmaceutical composition in form of an emulsion pre-concentrate. a unit dosage form comprising said composition, its use in therapy as well as a process for the preparation thereof.
- Non-steroidal anti-inflammatory drugs are well-known drugs for the treatment of pain and inflammation.
- One of the major drawbacks with NSAIDs is that they have severe gastro-intestinal side-effects. Patients undergoing treatment with NSAIDs for a longer period of time, such as naproxen, often experience problems with stomach gastrointestinal side-effects.
- Nitrogen oxide releasing NSAID compounds in the following NO-releasing NSAIDs, have recently been found to have an improved side-effect profile, see e.g. WO 94/04484, WO 94/12463, WO 95/09831 and WO 95/30641.
- NO-releasing NSAIDs are lipophilic compounds with poor aqueous solubility. They can be classified into class 2 according to the Biopharmaceutical Classification System proposed by Amidon et al. (Pharm. Res. 12 (1995) pp. 413-420). Drugs of this class are characterised by low aqueous solubility but reasonably well permeability. A biopharmaceutical problem with these compounds is that their absorption from the gastrointestinal tract (GIT) may be dissolution rate limited, resulting in poor bioavailibility upon oral administration.
- GIT gastrointestinal tract
- WO 95/08983 discloses a self-emulsifying composition for oral administration that forms a microemulsion in situ when in contact with biological fluids
- This composition can be characterised as a self-microemulsifying drug delivery system (SMEDDS), and comprises at least - an active compound.
- SMEDDS self-microemulsifying drug delivery system
- a lipophilic phase consisting of a mixture ot glyce ⁇ des and fatty acid esters.
- a surface-active agent consisting of a mixture ot glyce ⁇ des and fatty acid esters.
- a surface-active agent consisting of a mixture ot glyce ⁇ des and fatty acid esters.
- a surface-active agent consisting of a mixture ot glyce ⁇ des and fatty acid esters.
- a surface-active agent consisting of a mixture ot glyce ⁇ des and fatty acid esters
- a surface-active agent consisting of a mixture o
- compositions of WO 95/08983 comprise inter alia a cosurfactant in addition to a surface-active agent. The presence of a cosurfactant is not necessary for compositions of the present invention reducing toxicological concern to a minimum
- EP 274 870 discloses a pharmaceutical composition
- a pharmaceutical composition comprising a non-steroidal anti- lnflammatory drug (NSAID) and a surfactant, the composition being capable of forming micelles containing the NSAID upon oral administration.
- NSAID non-steroidal anti- lnflammatory drug
- GIT gastrointestinal tract
- Micelles are aggregates in which the surfactant molecules are generally arranged in a spheroidal structure with the hydrophobic region at the core shielded, in an aqueous solution, from the water by a mantle of outer hydrophilic regions.
- the drug is usually solubihsed in the surfactant.
- Micelles are to be contrasted in terms of their structure with emulsions which are formed by compositions of the present invention. Whereas micelles are thermodynamically stable one-phase-systems (according to the Gibbs phase law) in which the aggregates usually have a diameter of approximately two lengths of the surfactant molecule forming it, i.e.
- emulsions are much larger aggregates the order ot nanometers to micrometers in diameter, consisting ot an oilv core which is surrounded by one or several layers of surfactants Emulsions are generally two-phase-systems and they are thermodynamicallv unstable (but may be ineticallv stable)
- Another major difference between the compositions ot EP 274 870 and the present invention is the nature of the active compound Whereas NSAIDs are crystalline powders by nature, the NO-releasmg NSAIDs or mixtures of NO-releasing NSAIDs used in the present invention are in oil form or a thermosoftemng semisolid Moreover, micelles usually iequire a much higher drug surfactant ratio compared to the oil surfactant ratio required to form an emulsion
- NO-releasing NSAIDs are oils or thermosofte ng semisohds which are practically insoluble in water
- high- dose NO-releasing NSAIDs e g when the dose is above about 350 mg, it is difficult to formulate a tablet of reasonable size of the large amount of oil or semisolid
- the lipophilic NO-releasing NSAIDs can, however, be formulated as oil-in-water emulsions where the compound constitutes, or is part of, the oil phase emulsified in water by one or more surfactants
- the problems mentioned above have now been solved by providing a novel Self Emulsifying Drug Delivery System, commonly known as SEDDS, suitable for oral administration More particularly, the present invention is directed to a pharmaceutical composition suitable tor oral administration, in form of an emulsion pre-concentrate comprising
- composition forming an in-situ oil-in-water emulsion upon contact with aqueous media such as gastrointestinal fluids
- composition according to the present invention may optionally further comprise one or more short-chain alcohols
- the composition will form an in situ oil-in-water emulsion of small droplets of nanometer to micron size upon contact with gastrointestinal fluids, the droplets being constituted of a compound of the formula (I) above, forming the core of the droplet which is covered by one or several layers of surfactant
- the in situ formed oil-in-water emulsion will provide a good bioavailability of the compound of the formula (I) upon oral administration
- Storage stability of the emulsion is not a concern since the emulsion is not formed until the pre- concentrate has been taken by the patient, 1 e first at the moment of administration
- the possibly unpleasant taste of the pre-concentrate is not a problem when filled into capsules
- the pharmaceutical composition according to the present invention is an emulsion pre-concentrate at the time of administration to a patient
- the emulsion pre-concentrate can be filled into single unit dosage forms such as capsules, drinking ampoules and dose cushions, or may alternatively be formed as other suitable dosage forms such as chewable soft pills
- the emulsion pre- concentrate Upon contact with aqueous media such as gastrointestinal fluids, the emulsion pre- concentrate transforms into an oil-in-water emulsion
- the composition will form an in-situ oil-in-water emulsion in the gastrointestinal tract (GI tract)
- the drug release rate of the composition is determined by the droplet size of the in situ emulsion and the polarity ot the emulsion droplets, the latter being governed by the hydrophihc-lipophilic balance (HLB) of the drug/surfactant mixture, and the concentration of the surfactant
- HLB hydrophihc-lipophilic balance
- small droplet size and high polarity gives rise to a high drug release rate (N H Shah et al Int J Pharm 106 (1994) pp 15-23)
- the compound of the formula (I) above consists of naproxen, a butyl spacer and a NO-releasing moiety, said three parts being linked together into one single molecule Naproxen is by nature in form of a powder, whereas NO-releasing naproxen of the formula (I) above provides a compound in oil form as such at room temperature, due to the spacer
- NO-releasing naproxen of the formula (I) above provides a compound in oil form as such at room temperature, due to the spacer
- a pharmacologically inert oil or semisolid fat may be added to the pharmaceutical composition by means of a filler or as a viscosity regulator
- a filling agent may be required to increase dosing accuracy for low doses
- a viscosity regulator may be required in order to adjust optimal viscosity for filling of the composition into e g capsules In particular high speed liquid filling of capsules requires careful adjustment of viscosity within a range that prevents splashing on the low viscosity end and thread
- the total amount of the compound of the formula (I) used in the composition of the s invention is preferably in the range 50- 1500 mg per unit dose In still a further preferred embodiment, the amount of the compound of the formula (I) used in the composition is
- unit dose is defined as the amount ot active compound administered in one lo single capsule, or dissolved in one glass of water
- surfactant is defined as surface-active amphiphihc compounds such as block co-polymers
- Preferred surfactants in accordance with the present invention are non-ionic surfactants, for example those containing polyethylene glycol (PEG) chains, la particularly block co-polymers such as poloxamers
- poloxamers examples include Poloxamer 407 (Pluronic F127 "), Poloxamer 401
- Poloxamer 331 (Pluronic L101 ), Poloxamer 231 (Pluronic L81 ), tetrafunctional 0 polyoxyethylene polyoxypropylene block copolymer of ethylene diamine, known as
- Poloxamine 908 (Tetronic 908 ), Poloxamine 1307 (Tetronic 1307 " ), Poloxamine 1 107
- the total amount ot surtactant(s) in accordance with the invention may be within the range of from 12 5-6000 mg preferably of from 100-500 mg
- the ratio NO-releasing NSAID surfactant may vary from 1 0 1 to 1 10, preferably from 1 0 3 to 1 3
- ® ATO5 Gelucire is a mixture obtained by mixing mono-, di-, and t ⁇ -esters of glycerol, mono- and di-esters of PEG, or free PEG
- the pharmaceutical composition of the invention is filled into single dosage torms suitable for oral administration such as capsules, drinking ampoules and dose cushions or may be formulated as other suitable oral dosage forms such as chewable soft pills and chewy-base lozenges
- the pharmaceutical composition is filled into hard gelatin capsules but capsules from alternative materials such as methylcellulose- based shells, and soft gelatine capsules may also be used
- the pharmaceutical composition may be dissolved in e g a glass of water, thus allowing the pre-concentrate to form an emulsion which may be taken as an oral solution
- the compositions intended for dissolution prior to administration may be filled e g into sott gelatine capsules, plastic or aluminium cushions, or plastic or glass ampoules This feature is particularly advantageous for high dose compositions which would require a large capsule, for patients who have difficulty in swallowing capsules, and for pediat ⁇ c patients
- the pharmaceutical composition of the present invention is filled into capsules
- Preferred capsules are gelatin capsules which may be soft or hard
- the hard gelatine capsule consists of two pieces, a cap and a body, one fitting inside the other
- the hard gelatine capsules are produced empty and filled in a separate operation step
- the soft gelatin capsule is a capsule which is manufactured and filled in one single operation
- the emulsion pre-concentrate transforms into an oil-in-water emulsion upon contact with the gastrointestinal fluids, whereby the active drug is released
- the composition will form an in situ oil-in-water emulsion in the gastrointestinal tract (GI tract)
- the pharmaceutical composition of the present invention is particularly useful in the treatment of pain and inflammation
- pain is intended to include, but not limited to, nociceptive and neuropathic pain or combinations thereof acute, intermittent and chronic pain, cancer pain, migraine and headaches of similar origin
- inflammation ' is intended to include, but not limited to, rheumatoid arthritis ostheoarth ⁇ tis. and juvenile arthritis
- the pharmaceutical composition of the present invention may be prepared mainly by the following alternative methods
- the oily compound of the formula (I) is put in a vessel and fluid surfactant is added The mixture is mixed thoroughly until homogenous (visual inspection) and the pre-concentrate is filled into capsules suitable for oral administration
- the oily compound of the formula (I) is put in a vessel, finely grinded (particle size ⁇ 177 um) solid surfactant is added The liquid mixture is mixed thoroughly until homogenous (visual inspection) and the pre-concentrate is filled into capsules suitable for oral administration
- the semi-solid/sohd surfactant (s) is put in a vessel, and one or more alcohols are added The mixture is heated to the temperature corresponding to the melting point of the excipients, making the formulation fluid, mixed thoroughly until homogenous (visual inspection) The oily compound of the formula (I) is added, and the mixture is mixed thoroughly until homogenous (visual inspection). The pre-concentrate is filled into capsules suitable for oral administration.
- the formulation In order to fill a two-piece capsule or a softgel capsule with a liquid, the formulation must be within a certain viscosity range, as determined by the manufacturer, at the filling temperature suitable for the process. For a two-piece capsule the maximum filling temperature is roughly 70 °C.
- process temperature is not allowed to exceed 30-40 °C (the exact temperature depending on the manufacturer).
- the formulation must be liquid and have a viscosity that allows it to be pumpable at the filling temperature. In order to make the formulation liquid with an acceptable viscosity, several
- ® additives may be used, for example Cremophor EL .
- the composition is in liquid form at the temperature of filling.
- Semisolid thermosoftening compositions are therefore filled above the liqueifying temperature.
- Soft gelatine capsules are manufactured and filled in one operation, and may be filled at temperatures of up to 40 °C, whereas hard gelatine capsules may be filled at temperatures of up to 70 °C.
- Hard gelatin capsules filled with compositions that remain liquid at storage temperature require sealing, e.g. by gelatin banding, to prevent leakage.
- the process of liquid filling of hard gelatin capsules and product requirements are e.g. described in W.J. Bowtle, Pharmaceutical Technology Europe, October 1998; V.M.
- capsules permit filling of more than one phase into a single capsule which may be desired for bi-or multiphase drug release (W J Bow tie et al Int J Pharm 141 (1996) pp 9-16)
- phases ot solidifying material can be filled in single steps
- the final phase may be liquid if required
- the number of phases is only restricted by the capsule size, and volume ot the single phases
- This special feature may also allow controlled release or separation of different drug substances formulated in the same capsule
- capsules may be processed further e g by enteric coating
- the time for emulsion formation will vary from 30 seconds and up to 15 minutes, depending on the composition of the formulation If one or more short-chain alcohols are added, the time for emulsion formation will vary between 2-3 seconds and 3-4 minutes Also the average particle size of the formed emulsion is studied with Laser Diffraction, LD, or Photon Correlation Spectroscopy, PCS Depending on particle size either of the two methods may be used Detailed description of the invention
- a liquid formulation was prepared by mixing 1 kg of the liquid surfactant Poloxamer 401, with 1 kg of the compound of formula (I) at room temperature The liquid formulation was mixed until homogenous (checked by visual inspection) The resulting liquid formulation was then filled into hard gelatin capsules
- the active compound may be filled up to volume with aliquot part coconut oil.
- a semi-solid formulation was obtained by melting 1.500 kg of Pluronic F 127 ® (Poloxamer 407) by heating to 62 C. The melt was stirred thoroughly to ensure that no solid particles were present. 1.250 kg of the compound of formula (I) and 1.880 kg of fractionated coconut oil were added to the melted
- a liquid formulation was prepared A solution of 0 506 gram of Pluronic L101 (Poloxamer 331), 0 169 gram of sorbitanmonolaurat and 0 225 gram of ethanol, was mixed until homogenous (checked by visual inspection) 3 Grams of the compound of formula (I) was added to the mixture, at room temperature The resulting liquid formulation was then filled into soft gelatin capsules
- a pharmaceutical composition of the invention filled in a suitable unit dosage form according to the invention, was administered to each animal
- the dose levels were approximately 15 ⁇ mol/kg body weight 10 ml of tap water was given to facilitate the swallowing of the capsule or corresponding unit dosage
- Blood samples (5 ml) were taken from the jugular vein into Vacutainer tubes containing hepa ⁇ n Blood samples were taken before treatment (0) and at 15, 30 and 45 minutes. 1, 1 5, 2, 4, 7 and 24 hours after treatment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA02008658A MXPA02008658A (en) | 2000-03-08 | 2001-03-06 | New self emulsifying drug delivery system. |
SK1258-2002A SK285749B6 (en) | 2000-03-08 | 2001-03-06 | Pharmaceutical composition in form of emulsion pre-concentrate, unit dosage form containing thereof and its use |
PL358617A PL203549B1 (en) | 2000-03-08 | 2001-03-06 | The pharmaceutical composition in the form of an emulsion pre-concentrate, unit dosage form, and use of the pharmaceutical composition |
EEP200200483A EE200200483A (en) | 2000-03-08 | 2001-03-06 | New self-emulsifying drug delivery system |
AT01910304T ATE311173T1 (en) | 2000-03-08 | 2001-03-06 | NEW SELF-EMULSIFIING DRUG DELIVERY SYSTEM |
US10/221,079 US7736666B2 (en) | 2000-03-08 | 2001-03-06 | Self emulsifying drug delivery system |
EP01910304A EP1267831B1 (en) | 2000-03-08 | 2001-03-06 | New self emulsifying drug delivery system |
DE60115402T DE60115402T2 (en) | 2000-03-08 | 2001-03-06 | NEW SELF-SUCCESSING DRUG DISPOSAL SYSTEM |
CA002401857A CA2401857A1 (en) | 2000-03-08 | 2001-03-06 | New self emulsifying drug delivery system |
JP2001564740A JP4656479B2 (en) | 2000-03-08 | 2001-03-06 | Novel self-emulsifying drug delivery system |
KR1020027011733A KR100771318B1 (en) | 2000-03-08 | 2001-03-06 | New self emulsifying drug delivery system |
HU0300539A HU229103B1 (en) | 2000-03-08 | 2001-03-06 | Self emulsifying drug delivery system |
BRPI0109012-7A BR0109012B1 (en) | 2000-03-08 | 2001-03-06 | Pharmaceutical composition suitable for oral administration in the form of an emulsion pre-concentrate and unit dosage form. |
SI200130487T SI1267831T1 (en) | 2000-03-08 | 2001-03-06 | New self emulsifying drug delivery system |
AU2001237875A AU2001237875B2 (en) | 2000-03-08 | 2001-03-06 | New self emulsifying drug delivery system |
IL15138001A IL151380A0 (en) | 2000-03-08 | 2001-03-06 | New self emulsifying drug delivery system |
AU3787501A AU3787501A (en) | 2000-03-08 | 2001-03-06 | New self emulsifying drug delivery system |
UA2002086882A UA76098C2 (en) | 2000-03-08 | 2001-06-03 | System for drug delivery with capability for self-emulsification and method for treating pain and inflammation |
IS6538A IS6538A (en) | 2000-03-08 | 2002-09-03 | New self-contained drip system for administration |
NO20024194A NO331921B1 (en) | 2000-03-08 | 2002-09-03 | New self-emulsifying drug delivery system |
HK03106084A HK1053795A1 (en) | 2000-03-08 | 2003-08-25 | New self emulsifying drug delivery system |
US12/768,820 US20100266683A1 (en) | 2000-03-08 | 2010-04-28 | New self emulsifying drug delivery system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0000774-0 | 2000-03-08 | ||
SE0000774A SE0000774D0 (en) | 2000-03-08 | 2000-03-08 | New formulation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/768,820 Continuation US20100266683A1 (en) | 2000-03-08 | 2010-04-28 | New self emulsifying drug delivery system |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001066087A1 true WO2001066087A1 (en) | 2001-09-13 |
Family
ID=20278740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2001/000466 WO2001066087A1 (en) | 2000-03-08 | 2001-03-06 | New self emulsifying drug delivery system |
Country Status (29)
Country | Link |
---|---|
US (2) | US7736666B2 (en) |
EP (1) | EP1267831B1 (en) |
JP (1) | JP4656479B2 (en) |
KR (1) | KR100771318B1 (en) |
CN (1) | CN1283229C (en) |
AR (1) | AR027554A1 (en) |
AT (1) | ATE311173T1 (en) |
AU (2) | AU3787501A (en) |
BR (1) | BR0109012B1 (en) |
CA (1) | CA2401857A1 (en) |
CZ (1) | CZ303524B6 (en) |
DE (1) | DE60115402T2 (en) |
DK (1) | DK1267831T3 (en) |
EE (1) | EE200200483A (en) |
ES (1) | ES2253354T3 (en) |
HK (1) | HK1053795A1 (en) |
HU (1) | HU229103B1 (en) |
IL (1) | IL151380A0 (en) |
IS (1) | IS6538A (en) |
MX (1) | MXPA02008658A (en) |
MY (1) | MY137749A (en) |
NO (1) | NO331921B1 (en) |
RU (1) | RU2275908C2 (en) |
SE (1) | SE0000774D0 (en) |
SI (1) | SI1267831T1 (en) |
SK (1) | SK285749B6 (en) |
UA (1) | UA76098C2 (en) |
WO (1) | WO2001066087A1 (en) |
ZA (1) | ZA200207109B (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6613354B2 (en) | 1996-01-08 | 2003-09-02 | Astrazeneca Ab | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID |
WO2004000273A1 (en) * | 2002-06-25 | 2003-12-31 | Nicox S.A. | Oral pharmaceutical forms of liquid drugs having improved bioavailability |
WO2004076561A1 (en) * | 2003-02-27 | 2004-09-10 | Novasel Australia Pty Ltd | Poloxamer emulsion preparations |
WO2007012539A2 (en) * | 2005-07-26 | 2007-02-01 | Nicox S.A. | Pharmaceutical formulation of nitrooxyderivatives of nsaids |
US7465803B2 (en) | 2000-10-12 | 2008-12-16 | Nicox S.A. | Nitroderivatives as drugs for diseases having an inflammatory basis |
US8802116B2 (en) | 2003-02-27 | 2014-08-12 | Novasel Australia Pty. Ltd. | Poloxamer emulsion preparations |
US9788564B2 (en) | 2008-03-20 | 2017-10-17 | Virun, Inc. | Compositions containing non-polar compounds |
US10220007B2 (en) | 2008-03-20 | 2019-03-05 | Virun, Inc. | Compositions containing non-polar compounds |
US10335385B2 (en) | 2010-06-21 | 2019-07-02 | Virun, Inc. | Composition containing non-polar compounds |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0000773D0 (en) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
SE0102993D0 (en) * | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
DE10353937A1 (en) * | 2003-11-18 | 2005-06-30 | Fresenius Medical Care Deutschland Gmbh | Device for transferring a reference liquid into a measuring device, measuring device with such a device and method for transmitting a reference fluid into a measuring device |
GB0402679D0 (en) * | 2004-02-06 | 2004-03-10 | Novartis Ag | Organic compounds |
US8039018B2 (en) * | 2004-05-06 | 2011-10-18 | Emisphere Technologies, Inc. | Solid dosage form of wetted heparin |
JP5254610B2 (en) | 2004-05-14 | 2013-08-07 | エミスフェアー・テクノロジーズ・インク | Compounds and compositions for delivering active agents |
KR100654617B1 (en) * | 2004-09-23 | 2006-12-08 | 정해현 | the pack of coffee mix and the box of coffee mix with stick |
ES2661812T3 (en) | 2009-10-16 | 2018-04-04 | Mochida Pharmaceutical Co., Ltd. | Compositions |
US9968557B1 (en) | 2011-02-09 | 2018-05-15 | Florida A&M University | Method of preparing modified multilayered microstructures with enhanced oral bioavailability |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995008983A1 (en) * | 1993-09-30 | 1995-04-06 | Gattefosse S.A. | Oral delivery composition forming a microemulsion |
WO1995009831A1 (en) * | 1993-10-06 | 1995-04-13 | Nicox S.A. | Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation |
WO1999056727A2 (en) * | 1998-05-07 | 1999-11-11 | Elan Corporation, Plc | Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7804231L (en) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Gastric acid secretion |
GB2105193B (en) | 1981-09-04 | 1984-09-12 | Glaxo Group Ltd | Pharmaceutical compositions containing non-steroidal anti-inflammatory agents |
JPS59227870A (en) * | 1983-06-07 | 1984-12-21 | Yamanouchi Pharmaceut Co Ltd | Novel 2-guanidinothiazoline derivative and its preparation |
US4554276A (en) | 1983-10-03 | 1985-11-19 | Pfizer Inc. | 2-Amino-5-hydroxy-4-methylpyrimidine derivatives |
US4522826A (en) | 1984-02-08 | 1985-06-11 | Richardson-Vicks Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
US4552899A (en) * | 1984-04-09 | 1985-11-12 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
JPS6150978A (en) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | Pyridine derivative and preparation thereof |
AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
US4766117A (en) | 1984-10-11 | 1988-08-23 | Pfizer Inc. | Antiinflammatory compositions and methods |
US4676984A (en) | 1985-08-14 | 1987-06-30 | American Home Products Corp. | Rehydratable antacid composition |
US4704278A (en) | 1984-10-17 | 1987-11-03 | American Home Products Corp (Del) | Fluidized magaldrate suspension |
US4965065A (en) * | 1986-04-29 | 1990-10-23 | Bristol-Myers Squibb Company | Gastroprotective process and compositions |
US5037815A (en) | 1986-03-04 | 1991-08-06 | Bristol-Myers Squibb Co. | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers |
US4757060A (en) | 1986-03-04 | 1988-07-12 | Bristol-Myers Company | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers |
US5043358A (en) * | 1986-03-04 | 1991-08-27 | Bristol-Myers Squibb Company | Gastroprotective process |
GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
US5260333A (en) * | 1986-08-08 | 1993-11-09 | Bristol Myers Squibb Company | Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions |
GB8630273D0 (en) | 1986-12-18 | 1987-01-28 | Til Medical Ltd | Pharmaceutical delivery systems |
EP0320550A1 (en) | 1987-12-18 | 1989-06-21 | Bristol-Myers Company | Non steroidal anti-inflammatory drug composition containing H1 blockers, H2 blockers, beta adrenergic agonists or combinations thereof and an alkalizing agent |
SE8804629D0 (en) | 1988-12-22 | 1988-12-22 | Ab Haessle | NEW THERAPEUTICALLY ACTIVE COMPOUNDS |
NZ235877A (en) | 1989-11-02 | 1992-09-25 | Mcneil Ppc Inc | Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence |
US5204118A (en) | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
EP0574424A1 (en) * | 1991-03-04 | 1993-12-22 | Warner-Lambert Company | Novel salts/ion pairs of non-steroidal anti-inflammatory drugs in various dosage forms |
DE4131678A1 (en) | 1991-04-13 | 1992-10-15 | Beiersdorf Ag | STABLE MULTIPLE EMULSIONS |
DE69228738D1 (en) | 1991-12-06 | 1999-04-29 | Glaxo Group Ltd | Inflammatory or analgesic compositions containing ranitidine bismuth citrate and an NSAID |
WO1993012817A1 (en) | 1991-12-20 | 1993-07-08 | Warner-Lambert Company | Therapeutic combinations useful in the treatment of gastroesophageal reflux disease |
US5294433A (en) * | 1992-04-15 | 1994-03-15 | The Procter & Gamble Company | Use of H-2 antagonists for treatment of gingivitis |
IT1256345B (en) | 1992-08-20 | 1995-12-01 | NITRIC ESTERS OF PHENYLACETIC 2- (2,6-DI-HALO-PHENYLAMIN) DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION | |
JPH08502254A (en) | 1992-09-29 | 1996-03-12 | メルク エンド カンパニー インコーポレーテッド | Ibuprofen-H 2) Antagonist formulation |
IT1256450B (en) | 1992-11-26 | 1995-12-05 | Soldato Piero Del | NITRIC ESTERS WITH PHARMACOLOGICAL ACTIVITY AND PROCEDURE FOR THEIR PREPARATION |
US5686105A (en) * | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
CH686761A5 (en) * | 1993-05-27 | 1996-06-28 | Sandoz Ag | Pharmaceutical formulations. |
SE9301830D0 (en) | 1993-05-28 | 1993-05-28 | Ab Astra | NEW COMPOUNDS |
DK66493D0 (en) | 1993-06-08 | 1993-06-08 | Ferring A S | PREPARATIONS FOR USE IN TREATMENT OF INFLAMMATORY GAS DISORDERS OR TO IMPROVE IMPROVED HEALTH |
SE9302396D0 (en) | 1993-07-09 | 1993-07-09 | Ab Astra | A NOVEL COMPOUND FORM |
US6054136A (en) | 1993-09-30 | 2000-04-25 | Gattefosse S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
US6312704B1 (en) * | 1993-09-30 | 2001-11-06 | Gattefosse, S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
US5514663A (en) | 1993-10-19 | 1996-05-07 | The Procter & Gamble Company | Senna dosage form |
AU7961094A (en) | 1993-10-19 | 1995-05-08 | Procter & Gamble Company, The | Picosulphate dosage form |
US5643960A (en) * | 1994-04-15 | 1997-07-01 | Duke University | Method of delaying onset of alzheimer's disease symptoms |
US6025395A (en) * | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
DK0759899T3 (en) * | 1994-05-10 | 1999-12-20 | Nicox Sa | Nitro compounds and their compositions with anti-inflammatory, analgesic and antithrombotic activities |
KR100384960B1 (en) | 1994-07-08 | 2003-08-21 | 아스트라제네카 악티에볼라그 | Multi-Unit Tablet I |
SE9500478D0 (en) | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
WO1996033697A1 (en) * | 1995-04-24 | 1996-10-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Self-emulsifiable formulation producing an oil-in-water emulsion |
US5955451A (en) * | 1995-05-12 | 1999-09-21 | The University Of Texas System Board Of Regents | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
EP0760237A1 (en) | 1995-08-30 | 1997-03-05 | Cipla Limited | Oil-in-water microemulsions |
SE9600070D0 (en) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
US6231888B1 (en) | 1996-01-18 | 2001-05-15 | Perio Products Ltd. | Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps |
EP0941101A1 (en) | 1996-11-22 | 1999-09-15 | The Procter & Gamble Company | Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials |
SE510666C2 (en) | 1996-12-20 | 1999-06-14 | Astra Ab | New Crystal Modifications |
US6160020A (en) * | 1996-12-20 | 2000-12-12 | Mcneill-Ppc, Inc. | Alkali metal and alkaline-earth metal salts of acetaminophen |
SE510643C2 (en) * | 1997-06-27 | 1999-06-14 | Astra Ab | Thermodynamically stable omeprazole sodium form B |
BR9810729B1 (en) * | 1997-07-29 | 2010-07-13 | pharmaceutical composition for acid lipophilic compounds arranged as a self-emulsifying formulation. | |
AU9062998A (en) | 1997-09-11 | 1999-03-29 | Nycomed Danmark A/S | Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids) |
US6395298B1 (en) * | 1997-10-31 | 2002-05-28 | Pharmacia Corporation | Gellan gum tablet coating |
JP2002501896A (en) | 1998-01-30 | 2002-01-22 | セプラコール, インク. | S-lansoprazole compositions and methods |
JP2002501897A (en) | 1998-01-30 | 2002-01-22 | セプラコール, インク. | R-lansoprazole compositions and methods |
EP0984012A3 (en) | 1998-08-31 | 2001-01-10 | Pfizer Products Inc. | Nitric oxide releasing oxindole prodrugs with analgesic and anti-inflammatory properties |
DE69922394T2 (en) | 1998-09-28 | 2005-12-22 | Warner-Lambert Company Llc | DRUG DISPENSING IN THE THIN FERTILIZER AND THE THICK DARM USING HPMC CAPSULES |
US6485747B1 (en) * | 1998-10-30 | 2002-11-26 | Monsanto Company | Coated active tablet(s) |
KR100602725B1 (en) * | 1998-12-11 | 2006-07-20 | 파마솔루션스, 인코포레이티드 | Self-emulsifying compositions for drugs poorly soluble in water |
US6635281B2 (en) * | 1998-12-23 | 2003-10-21 | Alza Corporation | Gastric retaining oral liquid dosage form |
US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
WO2000057885A1 (en) | 1999-03-31 | 2000-10-05 | Pharmacia & Upjohn Company | Pharmaceutical emulsions for retroviral protease inhibitors |
IL145220A0 (en) | 1999-05-20 | 2002-06-30 | Par Pharmaceutical Inc | Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process |
TWI243672B (en) * | 1999-06-01 | 2005-11-21 | Astrazeneca Ab | New use of compounds as antibacterial agents |
US6126816A (en) * | 1999-07-14 | 2000-10-03 | Ruiz, Jr.; Reuben F. | Wastewater treatment device |
US20020102301A1 (en) * | 2000-01-13 | 2002-08-01 | Joseph Schwarz | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof |
US6787164B2 (en) | 2000-02-23 | 2004-09-07 | Bioselect Innovations, Inc. | Composition and method for treating the effects of diseases and maladies |
SE0000773D0 (en) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
US20020044962A1 (en) | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
SE0002476D0 (en) | 2000-06-30 | 2000-06-30 | Astrazeneca Ab | New compounds |
US6544556B1 (en) * | 2000-09-11 | 2003-04-08 | Andrx Corporation | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
US20020045184A1 (en) | 2000-10-02 | 2002-04-18 | Chih-Ming Chen | Packaging system |
FR2818905A1 (en) * | 2000-12-28 | 2002-07-05 | Cll Pharma | MICELLAR COLLOIDAL PHARMACEUTICAL COMPOSITIONS COMPRISING A LIPOPHILIC ACTIVE INGREDIENT |
AR036354A1 (en) | 2001-08-31 | 2004-09-01 | Takeda Chemical Industries Ltd | SOLID PREPARATION |
US7467633B2 (en) * | 2005-03-10 | 2008-12-23 | Huntsman Petrochemical Corporation | Enhanced solubilization using extended chain surfactants |
-
2000
- 2000-03-08 SE SE0000774A patent/SE0000774D0/en unknown
-
2001
- 2001-02-26 AR ARP010100864A patent/AR027554A1/en not_active Application Discontinuation
- 2001-03-06 AT AT01910304T patent/ATE311173T1/en active
- 2001-03-06 MX MXPA02008658A patent/MXPA02008658A/en active IP Right Grant
- 2001-03-06 HU HU0300539A patent/HU229103B1/en not_active IP Right Cessation
- 2001-03-06 KR KR1020027011733A patent/KR100771318B1/en not_active IP Right Cessation
- 2001-03-06 AU AU3787501A patent/AU3787501A/en active Pending
- 2001-03-06 IL IL15138001A patent/IL151380A0/en not_active IP Right Cessation
- 2001-03-06 WO PCT/SE2001/000466 patent/WO2001066087A1/en active IP Right Grant
- 2001-03-06 CA CA002401857A patent/CA2401857A1/en not_active Abandoned
- 2001-03-06 SK SK1258-2002A patent/SK285749B6/en not_active IP Right Cessation
- 2001-03-06 US US10/221,079 patent/US7736666B2/en not_active Expired - Fee Related
- 2001-03-06 CZ CZ20023006A patent/CZ303524B6/en not_active IP Right Cessation
- 2001-03-06 ES ES01910304T patent/ES2253354T3/en not_active Expired - Lifetime
- 2001-03-06 AU AU2001237875A patent/AU2001237875B2/en not_active Ceased
- 2001-03-06 EE EEP200200483A patent/EE200200483A/en unknown
- 2001-03-06 JP JP2001564740A patent/JP4656479B2/en not_active Expired - Fee Related
- 2001-03-06 BR BRPI0109012-7A patent/BR0109012B1/en not_active IP Right Cessation
- 2001-03-06 SI SI200130487T patent/SI1267831T1/en unknown
- 2001-03-06 RU RU2002122745/15A patent/RU2275908C2/en not_active IP Right Cessation
- 2001-03-06 DK DK01910304T patent/DK1267831T3/en active
- 2001-03-06 CN CNB018062938A patent/CN1283229C/en not_active Expired - Fee Related
- 2001-03-06 EP EP01910304A patent/EP1267831B1/en not_active Expired - Lifetime
- 2001-03-06 DE DE60115402T patent/DE60115402T2/en not_active Expired - Lifetime
- 2001-03-07 MY MYPI20011044A patent/MY137749A/en unknown
- 2001-06-03 UA UA2002086882A patent/UA76098C2/en unknown
-
2002
- 2002-09-03 IS IS6538A patent/IS6538A/en unknown
- 2002-09-03 NO NO20024194A patent/NO331921B1/en not_active IP Right Cessation
- 2002-09-04 ZA ZA200207109A patent/ZA200207109B/en unknown
-
2003
- 2003-08-25 HK HK03106084A patent/HK1053795A1/en not_active IP Right Cessation
-
2010
- 2010-04-28 US US12/768,820 patent/US20100266683A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995008983A1 (en) * | 1993-09-30 | 1995-04-06 | Gattefosse S.A. | Oral delivery composition forming a microemulsion |
WO1995009831A1 (en) * | 1993-10-06 | 1995-04-13 | Nicox S.A. | Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation |
WO1999056727A2 (en) * | 1998-05-07 | 1999-11-11 | Elan Corporation, Plc | Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6613354B2 (en) | 1996-01-08 | 2003-09-02 | Astrazeneca Ab | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID |
US8114435B2 (en) | 1996-01-08 | 2012-02-14 | Astrazeneca Ab | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID |
US7488497B2 (en) | 1996-01-08 | 2009-02-10 | Astrazeneca Ab | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID |
US7629368B2 (en) | 2000-10-12 | 2009-12-08 | Nicox S.A. | Nitroderivatives as drugs for diseases having an inflammatory basis |
US7465803B2 (en) | 2000-10-12 | 2008-12-16 | Nicox S.A. | Nitroderivatives as drugs for diseases having an inflammatory basis |
RU2323003C2 (en) * | 2002-06-25 | 2008-04-27 | Никокс С.А. | Oral pharmaceutical forms of liquid drugs showing improved bioavailability |
WO2004000273A1 (en) * | 2002-06-25 | 2003-12-31 | Nicox S.A. | Oral pharmaceutical forms of liquid drugs having improved bioavailability |
CN1319518C (en) * | 2002-06-25 | 2007-06-06 | 尼科克斯公司 | Oral pharmaceutical forms of liquid drugs having improved bioavailability |
US8802116B2 (en) | 2003-02-27 | 2014-08-12 | Novasel Australia Pty. Ltd. | Poloxamer emulsion preparations |
EP1597318A4 (en) * | 2003-02-27 | 2006-06-14 | Novasel Australia Pty Ltd | Poloxamer emulsion preparations |
EP1597318A1 (en) * | 2003-02-27 | 2005-11-23 | Novasel Australia Pty Ltd | Poloxamer emulsion preparations |
EA017434B1 (en) * | 2003-02-27 | 2012-12-28 | НОУВАСЕЛ ОСТРЕЙЛЮЭ ПиТиУай эЛТиДи | Stable local and/or mucosal emulsion preparations (embodiments), method for preparing (embodiments) and use thereof (embodiments) |
WO2004076561A1 (en) * | 2003-02-27 | 2004-09-10 | Novasel Australia Pty Ltd | Poloxamer emulsion preparations |
WO2007012539A3 (en) * | 2005-07-26 | 2007-04-19 | Nicox Sa | Pharmaceutical formulation of nitrooxyderivatives of nsaids |
WO2007012539A2 (en) * | 2005-07-26 | 2007-02-01 | Nicox S.A. | Pharmaceutical formulation of nitrooxyderivatives of nsaids |
US8691869B2 (en) | 2005-07-26 | 2014-04-08 | Nicox S.A. | Pharmaceutical formulation of nitrooxyderivatives of NSAIDs |
US9788564B2 (en) | 2008-03-20 | 2017-10-17 | Virun, Inc. | Compositions containing non-polar compounds |
US10220007B2 (en) | 2008-03-20 | 2019-03-05 | Virun, Inc. | Compositions containing non-polar compounds |
US10668029B2 (en) | 2008-03-20 | 2020-06-02 | Virun, Inc. | Compositions containing non-polar compounds |
US10335385B2 (en) | 2010-06-21 | 2019-07-02 | Virun, Inc. | Composition containing non-polar compounds |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100266683A1 (en) | New self emulsifying drug delivery system | |
CA2401498C (en) | New self emulsifying drug delivery system | |
AU2001237875A1 (en) | New self emulsifying drug delivery system | |
AU2001237876A1 (en) | New self emulsifying drug delivery system | |
EP1427392B1 (en) | New self emulsifying drug delivery system | |
PL203549B1 (en) | The pharmaceutical composition in the form of an emulsion pre-concentrate, unit dosage form, and use of the pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2002/01101/MU Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 151380 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 521008 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2401857 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12582002 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/07109 Country of ref document: ZA Ref document number: PA/a/2002/008658 Country of ref document: MX Ref document number: 200207109 Country of ref document: ZA Ref document number: 2001237875 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10221079 Country of ref document: US Ref document number: 02079427 Country of ref document: CO Ref document number: PV2002-3006 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 2001 564740 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027011733 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018062938 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001910304 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2002 2002122745 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2001910304 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027011733 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-3006 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001237875 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001910304 Country of ref document: EP |